<p><strong>Champions Oncology</strong>（納斯達克股票代碼：CSBR）將於 2025 年 12 月 15 日（星期一）發佈最新的季度財報。以下是投資者在公告前需要了解的內容。</p>
<p>分析師預計 Champions Oncology 將報告每股收益（EPS）為 0.01 美元。</p>
<p>Champions Oncology 的多頭希望聽到公司不僅超出該預期，還能提供積極的指引或下個季度的增長預測。</p>
<p>新投資者應注意，有時影響股票價格的並不是盈利的超出或未達預期，而是指引（或預測）。</p>
<h3>盈利記錄</h3>
<p>在上個季度，公司報告的每股收益超出預期 0.03 美元，導致次日股價下跌 16.02%。</p>
<p>以下是 Champions Oncology 的過去表現及其導致的價格變化：</p>
<table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2026 年第一季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">-0.01</td>
<td align="right">-0.20</td>
<td align="right">0.30</td>
<td align="right">0.01</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">0.02</td>
<td align="right">-0.07</td>
<td align="right">0.36</td>
<td align="right">0.05</td>
</tr>
<tr>
<td><strong>價格變化 %</strong></td>
<td align="right">-16.00</td>
<td align="right">-14.00</td>
<td align="right">-2.00</td>
<td align="right">-12.00</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1765548057_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1765548057_0.png"/></p>
<h3>股票表現</h3>
<p>截至 12 月 10 日，Champions Oncology 的股票交易價格為 6.3 美元。在過去 52 周內，股票上漲了 0.8%。鑑於這些回報通常是積極的，長期股東在此次財報發佈前應該感到滿意。</p>
<p>要跟蹤 Champions Oncology 的所有財報發佈，請訪問我們網站上的財報日曆。</p>
<p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>

CSBR

<p>Champions Oncology（納斯達克代碼：CSBR）將於 2025 年 12 月 15 日發佈季度財報。分析師預計每股收益（EPS）為 0.01 美元。投資者期待盈利超出預期，並對下個季度的指引持積極態度。上個季度，該公司每股收益超出預期 0.03 美元，但股價下跌了 16.02%。目前，股票交易價格為 6.3 美元，過去一年上漲了 0.8%</p>

<p><strong>Champions Oncology</strong> (NASDAQ: CSBR) is set to give its latest quarterly earnings report on Monday, 2025-12-15. Here's what investors need to know before the announcement.</p>
<div class="lb-trans"><p><strong>Champions Oncology</strong>（納斯達克股票代碼：CSBR）將於 2025 年 12 月 15 日（星期一）發佈最新的季度財報。以下是投資者在公告前需要了解的內容。</p>
</div><p>Analysts estimate that Champions Oncology will report an <strong>earnings per share</strong> (EPS) of $0.01.</p>
<div class="lb-trans"><p>分析師預計 Champions Oncology 將報告每股收益（EPS）為 0.01 美元。</p>
</div><p>Champions Oncology bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<div class="lb-trans"><p>Champions Oncology 的多頭希望聽到公司不僅超出該預期，還能提供積極的指引或下個季度的增長預測。</p>
</div><p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<div class="lb-trans"><p>新投資者應注意，有時影響股票價格的並不是盈利的超出或未達預期，而是指引（或預測）。</p>
</div><h3>Earnings Track Record</h3>
<div class="lb-trans"><h3>盈利記錄</h3>
</div><p>During the last quarter, the company reported an EPS beat by $0.03, leading to a 16.02% drop in the share price on the subsequent day.</p>
<div class="lb-trans"><p>在上個季度，公司報告的每股收益超出預期 0.03 美元，導致次日股價下跌 16.02%。</p>
</div><p>Here's a look at Champions Oncology's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是 Champions Oncology 的過去表現及其導致的價格變化：</p>
</div><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q1 2026</strong></th>
<th align="right"><strong>Q4 2025</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">-0.01</td>
<td align="right">-0.20</td>
<td align="right">0.30</td>
<td align="right">0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">0.02</td>
<td align="right">-0.07</td>
<td align="right">0.36</td>
<td align="right">0.05</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">-16.00</td>
<td align="right">-14.00</td>
<td align="right">-2.00</td>
<td align="right">-12.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2026 年第一季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">-0.01</td>
<td align="right">-0.20</td>
<td align="right">0.30</td>
<td align="right">0.01</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">0.02</td>
<td align="right">-0.07</td>
<td align="right">0.36</td>
<td align="right">0.05</td>
</tr>
<tr>
<td><strong>價格變化 %</strong></td>
<td align="right">-16.00</td>
<td align="right">-14.00</td>
<td align="right">-2.00</td>
<td align="right">-12.00</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1765548057_0.png" alt="eps graph" original-src="https://www.benzinga.com/files/images/story/2025/1765548057_0.png"/></p>
<h3>Stock Performance</h3>
<div class="lb-trans"><h3>股票表現</h3>
</div><p>Shares of Champions Oncology were trading at $6.3 as of December 10. Over the last 52-week period, shares are up 0.8%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.</p>
<div class="lb-trans"><p>截至 12 月 10 日，Champions Oncology 的股票交易價格為 6.3 美元。在過去 52 周內，股票上漲了 0.8%。鑑於這些回報通常是積極的，長期股東在此次財報發佈前應該感到滿意。</p>
</div><p>To track all earnings releases for Champions Oncology visit their earnings calendar on our site.</p>
<div class="lb-trans"><p>要跟蹤 Champions Oncology 的所有財報發佈，請訪問我們網站上的財報日曆。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>
</div>

前瞻洞察：Champions Oncology 的季度財報